0 projects

Date from new to old

EIC-The European Innovation Council (EIC)

NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY

The NOVO project will address a fundamental issue in proton radiotherapy (PT) of cancer, namely the lack of real-time dose verification (RDV) that significantly limits the potential of PT due to uncertainties in the precise delivery of the prescribed dose. In the NOVO project, we will develop the...

Awarded: NOK 17.8 mill.

Project Period: 2024-2028

Location: Vestland

EIC-The European Innovation Council (EIC)

Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.

Deep-lying cancers, such as glioblastoma multiforme (GBM) brain cancer, are very difficult to access and incurable by the current standards of care. The fluorescence of photosensitive molecules (PSs) can precisely guide surgical resection of GBM. Nevertheless, photomedical treatments like photody...

Awarded: NOK 25.2 mill.

Project Period: 2024-2028

Location: Oslo

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Human - Centric Indoor Climate for Healthcare Facilities

Over 4 million hospital patients acquire a healthcare-associated infection (HAI) in the EU each year. Moreover, the global crisis of antimicrobial resistance means that HAI is posing an increasing cost and risk of mortality. There is clear evidence that airflow controls the dispersion and exposur...

Awarded: NOK 9.0 mill.

Project Period: 2024-2027

Location: Trøndelag - Trööndelage

CL1-Health

The first European Digital Health Technology Assessment framework co-created by all stakeholders along the value chain

Awarded: NOK 21.5 mill.

Project Period: 2024-2027

Location: Akershus og 2 andre

CL1-Health

The malignant Glioma immuno-oncology matchmaker: towards data-driven precision medicine using spatially resolved radio-multiomics

Adult and paediatric malignant glioma (GBM and pHGG) remain among the most difficult-to-treat cancers with 5-year survival rates of <5% despite intensive standard-of-care therapy. The differences among patients and the heterogeneous and plastic nature of each individual tumour have resulted in al...

Awarded: NOK 12.2 mill.

Project Period: 2024-2028

Location: Oslo

CL1-Health

Multimodal 3D Holographic tool and real-time Guidance System with point-of-care diagnostics for surgical planning and interventions on liver and pancreatic cancers

Perioperative care is an intricate process that encompasses 1) preoperative evaluation, surgical planning and preparation; 2) intraoperative procedure; and 3) postoperative management. Perioperative care depends on clinical decision-making, a continuous process that involves many healthcare profe...

Awarded: NOK 44.6 mill.

Project Period: 2024-2027

Location: Oslo og 2 andre

MSCA-Marie Sklodowska-Curie Actions (MSCA)

DSTrain - Data Science Postdoctoral Training Programme

DSTrain is a 5-year postdoctoral programme that will award 36 postdoctoral fellowship positions of 36 months each in two calls over the programme period within the overarching frame of data science. The programme will train researchers and innovators with disciplinary, interdisciplinary and trans...

Awarded: NOK 52.1 mill.

Project Period: 2024-2028

Location: Akershus og 12 andre

CL1-Health

ENTEROVIRUS-LINKED TYPE 1 DIABETES EXPOSED -MECHANISMS AND PREVENTION

ENT1DEP aims to define causal links between infections and NCDs by focusing on enterovirus (EV) infections and type 1 diabetes (T1D), a robust association without proof of causality. Causality is addressed by a multidisciplinary, multi-layer approach, using in-vitro and in-vivo models, unique hum...

Awarded: NOK 7.3 mill.

Project Period: 2024-2027

Location: Oslo

CL1-Health

Targeting Epstein-Barr Virus Infection for Treatment and Prevention of Multiple Sclerosis

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system (CNS). It constitutes the most common non-traumatic cause of neurological impairment among young and middle-aged people and represents a major healthcare burden. Our recent research strongly i...

Awarded: NOK 29.6 mill.

Project Period: 2023-2028

Location: Buskerud og 5 andre

CL1-Health

Development of a global diagnostic ecosystem for detecting and monitoring emergency-prone pathogens across species and in a unified way

We aim to contribute to global diagnostics and preparedness for the next health crisis by developing in vitro diagnostic devices and methodologies for application at the point-of-care. For this purpose, mature as well as novel technologies and assays will be developed, addressing all pandemic pre...

Awarded: NOK 9.4 mill.

Project Period: 2023-2027

Location: Vestland

CL1-Health

PREDICTION OF ALZHEIMER’S DISEASE USING AN AI DRIVEN SCREENING PLATFORM

Awarded: NOK 11.9 mill.

Project Period: 2023-2027

Location: Rogaland

CL5-Climate, Energy and Mobility

From solar energy to fuel: A holistic artificial photosynthesis platform for the production of viable solar fuels

REFINE develops and demonstrates a system of artificial photosynthesis by combining both dark and light-dependent reactions for the direct production of high energy density and essential chemicals, such as alcohols. To achieve this, a direct hydrogen storage into hydrocarbons through CO2 capture ...

Awarded: NOK 21.8 mill.

Project Period: 2023-2027

Location: Oslo og 2 andre

ERC-European Research Council (ERC)

Targeting Acute Leukemia with TdT-TCR-T-cell therapy

Awarded: NOK 1.7 mill.

Project Period: 2023-2025

Location: Oslo og 2 andre

CL1-Health

PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials

Millions of people in the EU are negatively affected by cancer, and cancer is one of the leading causes of death and morbidity in Europe (ecis.jrc.europa.eu). The PRIME-ROSE consortium will contribute to the Mission Cancer goal to optimise treatment and support quality of life of more than 3 mill...

Awarded: NOK 18.2 mill.

Project Period: 2023-2028

Location: Oslo

CL1-Health

TOWARDS LARGE-SCALE ADAPTION AND TAILORED IMPLEMENTATION OF EVIDENCE-BASED PRIMARY CANCER PREVENTION PROGRAMMES IN EUROPE AND BEYOND

Awarded: NOK 1.8 mill.

Project Period: 2023-2027

Location: Vestland

CL1-Health

Reconstruction and Computational Modelling for Inherited Metabolic Diseases

Awarded: NOK 0.10 mill.

Project Period: 2023-2027

Location: Oslo

CL1-Health

International Study for Treatment of Childhood Relapsed ALL 2020

Relapse of acute lymphoblastic leukemia (ALL) remains a leading cause of mortality in childhood cancer. IntReALL 2020 will conduct randomized and historically controlled trials in children with relapsed B-cell precursor (BCP) ALL with the aim to replace toxic chemotherapy with better tolerated an...

Awarded: NOK 1.1 mill.

Project Period: 2023-2028

Location: Oslo

CL1-Health

COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE

Cancer is the second leading cause of death in Europe with an expected increase of about 25% by 2035. A wide and unacceptable variability in terms of access to research, innovation and quality care exists between and within countries. Possible solutions are an increase in knowledge by funding res...

Awarded: NOK 3.2 mill.

Project Period: 2023-2026

Location: Oslo

CL1-Health

IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs

Awarded: NOK 3.7 mill.

Project Period: 2023-2028

Location: Akershus

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Guiding glioblastoma treatments by decrypting tumor biomechanics via Magnetic Resonance Elastography.

Glioblastoma multiforme (GBM) is the most common and deadly type of primary brain tumour, carrying a dire prognosis with a median survival of 14.6 months for patients undergoing standard treatments. The causes of poor clinical prognosis are late diagnosis, diffuse infiltration, pseudo necrosis, h...

Awarded: NOK 2.9 mill.

Project Period: 2023-2026

Location: Oslo

CL1-Health

Establishing of Cancer Mission Hubs: Networks and Synergies

Cancer- healthcare, research and innovation face core common challenges, such as fragmentation of initiatives and distancing from important stakeholders, requiring coordinated solutions. These challenges are recognized in Horizon Europe’s Cancer Mission Implementation Plan and in Europe’s Beating...

Awarded: NOK 3.7 mill.

Project Period: 2023-2026

Location: Oslo og 3 andre

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Combination therapy for the treatment of metastatic melanoma using magnetic nanoparticles

Awarded: NOK 3.0 mill.

Project Period: 2023-2027

Location: Oslo

CL1-Health

Quality of Life in Oncology: measuring what matters for cancer patients and survivors in Europe

Awarded: NOK 7.6 mill.

Project Period: 2023-2026

Location: Oslo

MSCA-Marie Sklodowska-Curie Actions (MSCA)

Determining Genetic Bases of Differential Response to Antipsychotics Using Patient-Derived Neurons

Schizophrenia (SCZ) affects 20 million people worldwide and antipsychotics remain the only effective pharmacological intervention. However, one-third of people with SCZ do not respond to first-line antipsychotic drugs. In the absence of clinical biomarkers to stratify SCZ subtypes, all individual...

Awarded: NOK 3.1 mill.

Project Period: 2023-2025

Location: Vestland

CL1-Health

CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE

Rare tumour risk syndromes (RTRS) are rare diseases, affecting 5 per 10.000 people or less and caused by heritable genetic variants. In RTRS, the lifetime risk to develop various cancers can be as high as 100%, and patients have a 50% chance of transmitting the disease to their offspring. When un...

Awarded: NOK 3.5 mill.

Project Period: 2023-2025

Location: Vestland

WIDENING-Widening participation and spreading excellence

Diabetes, obesity and the Kidney

Chronic kidney disease is a major cause of morbidity and mortality in the EU. About 10-15% of the EU population has chronic kidney disease (CKD) and this number is expected to increase in the future decades. Diabetes is today the main cause of CKD in the EU: about, 30% of the cases with dialysi...

Awarded: NOK 2.9 mill.

Project Period: 2023-2025

Location: Oslo

ERC-European Research Council (ERC)

Final act of the autophagy symphony: Whole-organism orchestration of autophagy termination

Awarded: NOK 15.2 mill.

Project Period: 2023-2027

Location: Oslo

CL1-Health

Maximising Impact of Prescription Drugs in Rheumatoid Arthritis

Awarded: NOK 21.1 mill.

Project Period: 2022-2027

Location: Oslo

CL1-Health

Fostering a European Research Area for Health Research

Awarded: NOK 15.8 mill.

Project Period: 2022-2029

Location: Vestland og 2 andre

EIC-The European Innovation Council (EIC)

Supervised morphogenesis in gastruloids

The lack of realistic in vitro organ models that can faithfully represent in vivo physiological processes is a major obstacle affecting the biological and medical sciences. The current gold standard is animal experiments, but it is increasingly clear that these models mostly fail to recapitulate ...

Awarded: NOK 13.6 mill.

Project Period: 2022-2027

Location: Oslo

1 2 3 4 5